We are live on ! Find out more

iShares US Pharmaceuticals ETF

IHE

Market cap $1.62B

101.07 USD

-0.20

0.2%

At close Updated Sep 11, 4:00 PM EDT

1 day

-0.2%

5 days

-3.28%

1 month

-1.72%

3 months

6.31%

6 months

14.33%

Year to date

19.09%

1 year

40.88%

5 years

60.66%

10 years

100.73%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 29.4%

Neutral 52.9%

Negative 17.6%

IHE: Innovation Supports The Outlook, Valuation Limits Conviction

iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity therapies, robust drug pipelines, and demographic tailwinds but faces high concentration risk. Short-term catalysts include LLY's earnings momentum, FDA drug approvals, sector M&A activity, and potential interest rate improvements.

IHE: Innovation Supports The Outlook, Valuation Limits Conviction

IHE: Large-Cap Pharma Cools After A Hot Summer

I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings totaling 76%. Technical trends have turned concerning, with a recent breach of trendline support and a possible 10% correction to $97 likely through October.

IHE: Large-Cap Pharma Cools After A Hot Summer

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

The Motley Fool

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry, while XLV spreads its bets across the broader healthcare sector.

XLV vs. IHE: Which Healthcare ETF Is the Better Buy?

Zacks Investment Research

Will Generic Drug Tariffs Impact Pharma ETFs?

New U.S. tariffs on generic drugs could pressure drugmakers and influence pharmaceutical ETFs. Here's what investors should watch.

Will Generic Drug Tariffs Impact Pharma ETFs?

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge excluding Japan was little changed after swinging between gains and losses.

Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide

The Motley Fool

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

Vanguard Health Care ETF offers a significantly lower expense ratio of 0.09% compared to 0.38% for iShares U.S. Pharmaceuticals ETF iShares U.S. Pharmaceuticals ETF has delivered higher total returns over the last five years but carries higher concentration risk with only 56 holdings Vanguard Health Care ETF provides broader sector diversification by covering the entire medical ecosystem while the iShares fund focuses strictly on drug manufacturers

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

Kospi jumps 6% as Asia's battered semiconductor trade rebounds

Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a barrel. MSCI's Asia-Pacific gauge outside Japan gained 1.2%, while South Korea's Kospi surged more than 6% and Japan's Nikkei 225 climbed 1.9%.

Kospi jumps 6% as Asia's battered semiconductor trade rebounds

The Motley Fool

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

The Motley Fool

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

iShares Global Healthcare ETF provides exposure to 110 international stocks, whereas iShares U.S. Pharmaceuticals ETF concentrates on 56 domestic companies iShares U.S. Pharmaceuticals ETF has higher concentration risk with its two largest holdings accounting for over 43.00% of the total portfolio iShares U.S. Pharmaceuticals ETF has outperformed on a one-year and five-year total return basis compared to iShares Global Healthcare ETF

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

See News Rankings

Price charts implemented using Lightweight Charts™